-
Mashup Score: 2Sinister secret of ancestry DNA testing - 2 day(s) ago
Just three years ago, 23andMe was being hailed as Silicon Valley’s latest golden success story, with 15million subscribers and a share price higher than Apple’s.
Source: www.dailymail.co.ukCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 1
Experts worry RFK could put out misinformation on the effects of fluoride that would harm public health.
Source: www.statnews.comCategories: General Medicine News, Rare DiseaseTweet-
When I was little, it was pretty normal for adults to need full dentures. When I was in grade school, fluoridated toothpaste was developed, then addition to water supplies. What a difference. RFKjr is frightening. https://t.co/YjQ0uRsEFE via @statnews
-
-
Mashup Score: 0Bluesky Is Turning Into a Strong X Alternative - 2 day(s) ago
Bluesky has a hint of the old Twitter magic, but the feeling of freedom it offers might be even better.
Source: www.nytimes.comCategories: General Medicine News, Rare DiseaseTweet-
https://t.co/jC2xggHHVZ
-
-
Mashup Score: 1After ALS trial misses mark, Seelos has filed for bankruptcy - 3 day(s) ago
After Seelos Therapeutics’ amyotrophic lateral sclerosis (ALS) candidate failed a phase 2/3 study, the biotech has filed for bankruptcy. | After Seelos Therapeutics’ amyotrophic lateral sclerosis (ALS) candidate failed a phase 2/3 study, the biotech has filed for chapter 11 bankruptcy.
Source: www.fiercebiotech.comCategories: General Medicine News, Rare DiseaseTweet-
After ALS trial misses mark, Seelos has filed for bankruptcy https://t.co/CNno2yq0NG
-
-
Mashup Score: 1
Experts worry RFK could put out misinformation on the effects of fluoride that would harm public health.
Source: www.statnews.comCategories: General Medicine News, Rare DiseaseTweet-
When I was little, it was pretty normal for adults to need full dentures. When I was in grade school, fluoridated toothpaste was developed, then addition to water supplies. What a difference. RFKjr is frightening. https://t.co/YjQ0uRsEFE via @statnews
-
-
Mashup Score: 0Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS — Verge Genomics - 5 day(s) ago
— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics’ AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of the Robust Predictive Power of CONVERGE® – 83% of Prioritized Targets were Validated in Disease-Relevant Models, a Rate Significantly Higher than Industry S
Source: www.vergegenomics.comCategories: General Medicine News, Rare DiseaseTweet-
https://t.co/kEXB1nippH
-
-
Mashup Score: 0Neurizon Drug Cuts ALS Target Aggregation - 5 day(s) ago
Melbourne-based company Neurizon Therapeutics has announced positive results from a preclinical study of its lead candidate, NUZ-001.Amyotrophic
Source: www.miragenews.comCategories: General Medicine News, Rare DiseaseTweet-
https://t.co/j87pc8pMuK
-
-
Mashup Score: 0Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association - 5 day(s) ago
**media[470184]**
Source: www.manilatimes.netCategories: General Medicine News, Rare DiseaseTweet-
https://t.co/MovmwDjyDG
-
-
Mashup Score: 0Trace Neuroscience Nets $101M in Series A Funding for ALS, Dementia Therapy Development - 5 day(s) ago
Trace Neuroscience Nets $101M in Series A Funding for ALS, Dementia Therapy Development Biopharmaceutical company Trace Neuroscience announced it
Source: seniorhousingnews.comCategories: General Medicine News, Rare DiseaseTweet-
https://t.co/OkkKmqDIXb
-
-
Mashup Score: 0QurAlis' ANQUR Clinical Trial of QRL-201 in ALS Advances to Dose Range-Finding (DRF) Phase With First Participant Dosed - 5 day(s) ago
CAMBRIDGE, Mass., Nov. 19, 2024 /PRNewswire/ — QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative and neurological diseases, today announced that the Phase 1 ANQUR clinical trial evaluating QRL-201 for the treatment of ALS has successfully completed the dose-escalation phase, based on
Source: www.biospace.comCategories: General Medicine News, Rare DiseaseTweet-
https://t.co/4fTgiReZDW
-
RT @ArthurCaplan: Sinister secret of ancestry DNA testing https://t.co/tSZUvjpQom via @MailOnline